Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170670 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL8953481 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL3351318 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL30759409 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL16815808 | 0.85 | SMN1; SMN2 (0.44) | PPARGPPARASMN1; SMN2PTPRAKDM6B | |
| SCHEMBL28185307 | 0.85 | SMN1; SMN2 (0.44) | PPARGPPARASMN1; SMN2PTPRAKDM6B | |
| SCHEMBL7274320 | 0.82 | CYP1A2 (0.55) | PPARGPPARAALDH1A1KMT2AMEN1 | |
| SCHEMBL8953483 | 0.81 | PPARG (0.56) | PPARGPPARASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6443526 | 0.79 | KDM4E (0.51) | PPARGPPARASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7506333 | 0.79 | PPARG (0.54) | PPARGPPARAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-104725397-B | Thienopyrimidine derivative, its preparation method and the Pharmaceutical composition containing them | 法国施维雅药厂 | 2017-11-28 | — | — | CN | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2327767-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2319919-A1 | Nitrilases | Verenium Corporation (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1578910-A4 | NITRILASES | VERENIUM CORP (US) | 2008-06-04 | — | — | EP | disclosed |
| CN-1849391-A | Nitrilases, nucleic acids encoding nitrilases, and methods of making and using the same | DIVERSA CORP (US) | 2006-10-18 | — | — | CN | disclosed |
| EP-1578910-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-0634408-B1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| CN-1039331-C | Depsispeptide derivative, preparation and application of same | FUJISAMA PHARMACEUTICAL CO LTD (JP) | 1998-07-29 | — | — | CN | disclosed |
| EP-0634408-A1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
| CN-1080932-A | Depsipeptide derivative and manufacture method thereof and purposes | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | PPARG 2133/4885PPARA 3452/4885SMN1; SMN2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.